By 2025-End, Global Immuno-Oncology Market Will
Reach a Valuation of US$ 27,846.3 Mn
Owing to higher efficiency as compared to conventional therapies such as radiation, chemo and
surgery, doctors around the globe are increasingly prescribing immunotherapy to cancer patients.
Immuno-oncology therapies have low toxicity, making it easier for the patients to undergo such
treatment procedures. Increasing clinical approval of immunotherapy drugs continues to support
speedy adoption of immuno-oncology treatments while higher investments to further improve
immunotherapies is anticipated to create greater market opportunities for drug makers. Persistence
Market Research (PMR) is its latest report projects that the global market for immune-oncology is set
to witness a CAGR of 16.5% between 2016 and 2025, to reach a valuation of US$ 27,846.3 Mn by
the end of the forecast period.
Collaborative efforts and initiatives to identify therapies for difficult-to-treat illnesses is a key factor
driving the overall immune-oncology market. However, high drug pricing, development costs and
limited technical expertise are some of the challenges likely to dampen the surging spirit of the
market over 2025.
Download Sample Report @ http://www.persistencemarketresearch.com/samples/11329
Currently, immune checkpoint inhibitor therapy is widely used for treating several carcinogenic
disorders. Immune checkpoint inhibitor drugs help the body fight against certain proteins that are
normally used by various tumors to suppress immune responses. Sales revenue from immune
checkpoint inhibitors drugs is anticipated to reach US$ 7,321.7 Mn by 2017-end. Of late, a number
immune checkpoint inhibitor drugs have been approved by the US FDA including Yervoy (anti-
CTLA-4), Opdivo and Keytruda (anti-PD1) and Tecentriq (anti-PD-L1). Demand for these drugs is
expected to further gain traction, owing to a significant investment by biopharmaceutical companies
in developing a robust pipeline. Meanwhile, immune system modulator is the second most preferred
immune-oncology therapy and is expected to create an incremental opportunity of US$ 659.9 Mn
between 2017 and 2025. Two major approved drugs that fall in this category include interferons and
interleukins.
Based on therapeutic area, demand for immune-oncology therapeutics for melanoma will remain
high throughout the forecast period. By end user, hospitals account for the largest revenue share of
the market and are expected to represent around US$ 5,557.1 Mn by 2017-end.
Download Report Table of Content, Figures, and Tables @
http://www.persistencemarketresearch.com/market-research/immunooncology-market/toc
Amongst regions, the immuno-oncology market in North America accounted for a revenue
share of around 67.1% in 2016. The region’s market is expected to witness a strong CAGR of 17.1%
during the assessment period and retain its top position. In terms of revenue, the US dominates the
North America immuno-oncology market and is projected to continue to do so in 2017 and beyond
owing to the presence of prominent drug manufacturing companies in the country.
PMR is its report has profiled some of the leading companies operating in the global immunooncology market, which includes Amgen, Inc., AstraZeneca Plc, Bristol-Myers Squibb, Dendreon
Corporation, F.Hoffmann-La Roche, Merck & Co., Inc. Novartis AG, Pfizer, Inc., Sanofi. In terms of
revenue share, Bristol-Myers Squibb (BMS) was ranked at the top in 2016, thanks to the success of
its blockbuster products Opdivo and Yervoy.
Browse Complete Report @ http://www.persistencemarketresearch.com/market-
research/immunooncology-market.asp
About Us:
Persistence Market Research (PMR) is a third-platform research firm. Our research model is a
unique collaboration of data analytics and market research methodology to help businesses achieve
optimal performance.
To support companies in overcoming complex business challenges, we follow a multi-disciplinary
approach. At PMR, we unite various data streams from multi-dimensional sources. By deploying
real-time data collection, big data, and customer experience analytics, we deliver business
intelligence for organizations of all sizes.
Our offerings include pre-built reports that address every major sale, customized solutions to cater to
client-specific needs, and consulting services to offer more value addition. Our next-generation
research approach for exploring emerging technologies has allowed us to solve the most complex
problems of clients. We do not follow a reactive approach, but a pro-active one. Expert analysts at
PMR keep a tab on next-generation technologies in their R&D phase and provide the latest insights
into these technologies when they are being commercialized. Our ground-breaking approach allows
us to deliver market solutions before the technologies reach the market.
Our client success stories feature a range of clients from Fortune 500 companies to fast-growing
startups. PMR’s collaborative environment is committed to building industry-specific solutions by
transforming data from multiple streams into a strategic asset.
Contact Us:
Persistence Market Research
90 Sate Street, Suite 700 Albany, NY 12207
Tel: +1-518-618-1030
Email: [email protected]
Website: http://www.persistencemarketresearch.com/
[email protected]
Stay updated with our official Blog: http://pmrblog.com